ReviewTranslational psychiatry2021
Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions.
Review in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 61 citations in OpenAlex.
- Direct and indirect associations linking COVID-19 severity to internalizing disorders and symptoms among participants in New Haven, CT.Journal of affective disorders · 2026Article
- Neurocognitive and Neuropsychiatric Trajectories in a Post-COVID Cohort: A Descriptive Longitudinal Study.Neurology international · 2026Article
- Cognitive and Neuropsychiatric Sequelae After SARS-CoV-2 Infection: A Narrative Review and Exploratory Cross-Sectional Study of Neurofilament Light Chain and GFAP.Brain sciences · 2026Article
- Neuroimmune Mechanisms and Emerging Intervention Strategies for Post-Stroke Fatigue: A Narrative Review.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- COVID-19-associated neurological and psychological manifestations.Nature reviews. Disease primers · 2025Review
- Physical, cognitive, and mental health impacts of Omicron reinfection in patients with original SARS-CoV-2 infection: a community-based observational study.BMC medicine · 2025Observational
- Association between mental health symptoms and autoimmunity in patients with long COVID.BMC infectious diseases · 2025Observational
- Cognitive impairment 2 years after mild to severe SARS-CoV-2 infection in a population-based study with matched-comparison groups.Scientific reports · 2025Article
- Acute Schizophrenia-like Psychotic Disorder Against the Background of COVID-19.Medicina (Kaunas, Lithuania) · 2025Observational
- Systematic review and meta-analysis of brain neuroimaging abnormalities in COVID-19 patients and survivors.Psychoradiology · 2025Article
- Neuropsychiatric Manifestations of COVID-19 Disease and Post COVID Syndrome: The Role of N-acetylcysteine and Acetyl-L-carnitine.Current neuropharmacology · 2025Review
- Review
- Multi-target drugs for the treatment of cognitive impairment and fatigue in post-COVID syndrome: focus on Ginkgo biloba and Rhodiola rosea.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Unmasking the long-term effects: unravelling neuropsychiatric and neurological consequences of COVID-19.Annals of medicine and surgery (2012) · 2024Review
- Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.Frontiers in immunology · 2024Review
- Non-coding RNAs expression in SARS-CoV-2 infection: pathogenesis, clinical significance, and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- Epidemiology, clinical presentation, pathophysiology, and management of long COVID: an update.Molecular psychiatry · 2023Review
- COGNITIVE, NEUROLOGICAL, NEUROPSYCHOLOGICAL AND NEUROPSYCHIATRIC ALTERATIONS IN POST-COVID-19 PATIENTS.Actas espanolas de psiquiatria · 2023Article
- Review
- Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has caused large-scale economic and social losses and worldwide deaths. Although most COVID-19 patients have initially complained of respiratory insufficiency, the presence of neuropsychiatric manifestations is also reported frequently, ranging from headache, hyposmia/anosmia, and neuromuscular dysfunction to stroke, seizure, encephalopathy, altered mental status, and psychiatric disorders, both in the acute phase and in the long term. These neuropsychiatric complications have emerged as a potential indicator of worsened clinical outcomes and poor prognosis, thus contributing to mortality in COVID-19 patients. Their etiology remains largely unclear and probably involves multiple neuroinvasive pathways. Here, we summarize recent animal and human studies for neurotrophic properties of severe acute respiratory syndrome coronavirus (SARS-CoV-2) and elucidate potential neuropathogenic mechanisms involved in the viral invasion of the central nervous system as a cause for brain damage and neurological impairments. We then discuss the potential therapeutic strategy for intervening and preventing neuropsychiatric complications associated with SARS-CoV-2 infection. Time-series monitoring of clinical-neurochemical-radiological progress of neuropsychiatric and neuroimmune complications need implementation in individuals exposed to SARS-CoV-2. The development of a screening, intervention, and therapeutic framework to prevent and reduce neuropsychiatric sequela is urgently needed and crucial for the short- and long-term recovery of COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.